WO1992005193A1 - Plasmodium liver stage antigens - Google Patents
Plasmodium liver stage antigens Download PDFInfo
- Publication number
- WO1992005193A1 WO1992005193A1 PCT/GB1991/001605 GB9101605W WO9205193A1 WO 1992005193 A1 WO1992005193 A1 WO 1992005193A1 GB 9101605 W GB9101605 W GB 9101605W WO 9205193 A1 WO9205193 A1 WO 9205193A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pbl
- liver stage
- genomic
- berghei
- cdna fragment
- Prior art date
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 42
- 239000000427 antigen Substances 0.000 title claims abstract description 38
- 108091007433 antigens Proteins 0.000 title claims abstract description 38
- 102000036639 antigens Human genes 0.000 title claims abstract description 38
- 241000224016 Plasmodium Species 0.000 title claims abstract description 11
- 241000224017 Plasmodium berghei Species 0.000 claims abstract description 26
- 239000002299 complementary DNA Substances 0.000 claims abstract description 15
- 241000223960 Plasmodium falciparum Species 0.000 claims abstract description 9
- 206010035503 Plasmodium vivax infection Diseases 0.000 claims abstract description 3
- 241000223810 Plasmodium vivax Species 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 25
- 244000045947 parasite Species 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 210000004408 hybridoma Anatomy 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- 230000000078 anti-malarial effect Effects 0.000 claims description 4
- 239000003430 antimalarial agent Substances 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 3
- 238000001890 transfection Methods 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 31
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 210000003046 sporozoite Anatomy 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 7
- 240000009188 Phyllostachys vivax Species 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 101710117490 Circumsporozoite protein Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000001563 schizont Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000003936 merozoite Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000003934 vacuole Anatomy 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000009182 Parasitemia Diseases 0.000 description 3
- 208000030852 Parasitic disease Diseases 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 229940044627 gamma-interferon Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000003812 trophozoite Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000223830 Plasmodium yoelii Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 244000000011 human parasite Species 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000224021 Plasmodium berghei ANKA Species 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 239000007160 ty medium Substances 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
- C07K16/205—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to the isolation and production of a ⁇ tigenic proteinaceous material from parasites of the genus Plasmodium, the production of monoclonal antibodies responsive thereto, and anti-malarial vaccines containing them.
- the mammalian malarial sporozoite invades the hepatocyte wherein it multiplies for the next 2-15 days (dependant on the parasite species). Thereafter liver merozoites are released into the blood stream in which the intra-erthrocytic sexual and pathogenic asexual stages then proliferate initiating the blood stage of the disease responsible for the symptoms and pathology of malaria. Malaria vaccines based on antigens from the sporozoite (Herrington, et al., 1987), asexual blood stages (Patarroyo, et al., 1988) and sexual stages (Carter, et al., 1988) are currently being evaluated.
- liver stages antigens have been little studied as possible vaccine candidates because these intracellular stages were considered to be inaccessible to the immune system of the host (Cox, 1988). It is now clear from studies in rodent models (P. berghei and P. yoelii), however, that a substantial part of the protection afforded by immunising with irradiated sporozoites results from CD8+ T cell activity directed against the infected hepatocyte rather than from antibodies directed against the circumsporozoite proteins (CSP) on the circulating sporozoites (Weiss, 1987; Schofield, et al., 1987; Hoffman, et al., 1989).
- CSP circumsporozoite proteins
- Processed CSP associated with the class 1 major histocompatability complex on the surface of the infected liver cell appears to be one target for such cytotoxic T cells (Kumar, et al., 1988; Sadoff, et al., 1988 ; Hoffman, et al., 1989a; Romero, et al., 1989).
- the single CD8+ T cell epitope of P. falciparum CSP shows a high degree of polymorphism (Loc yer, et al., 1989) and the response to it may also be geneticaDy restricted (Good, et al., 1988).
- liver stage parasite can be killed by cytokines (principally gamma interferon) (Mazier, et al., 1988; Scholfield, et al., 1987) and phagocytes (Shortt & Garnham, 1984; Terzakis, et al., 1979; Meis, et al., 1987) further highlight the need to identify the antigens relevant to liver stage immunity.
- cytokines principally gamma interferon
- phagocytes Shortt & Garnham, 1984; Terzakis, et al., 1979; Meis, et al., 1987
- a liver stage antigen (Pbl 1) has been identified and isolated from cultures of Plasmodium berghei and a monoclonal antibody (anti-Pbl 1) produced specific to that antigen.
- a purified isolate comprising the P. berghei liver stage antigen Pbl 1, and Pbl 1 homologues from the genus Plasmodium, especially P. falciparum and P. vivax (referred to herein as homologous Pbl 1).
- Liver stage antigens according to 1 obtained by the expression of genomic or cDNA encoding therefor in an expression vehicle.
- Anti-malarial vaccines comprising a Plasmodium liver stage antigen according to 1 or 2, or a monoclonal antibody according to 3.
- the present invention provides:
- a purified isolate comprising the liver stage antigen of P.berghei identified herein as Pbl 1.
- the P. berghei liver stage antigen identified herein as Pbl 1 has been identified in vivo as localised to the parasitophorous vacuole, i.e. the space surrounding the infecting parasite in the infected hepatocyte, and on the surface of the parasitophorous vacuole membrane .
- Molecular weight studies on the isolated antigen indicate a molecular weight (Mr) of 35 + 5 kDA.
- the antigen is specifically recognised by monoclonal antibody 23.46.7 (hereinafter described).
- the antigen is expressed throughout the liver stage of the infection by P. berghei from 3-5 hours post-invasion by the infecting sporozoites to the release of the merzoites from the liver into the blood stream.
- the present invention also extends to Pbl 1 homologues from parasites of the genus Plasmodium, and more especially the human parasites P. falciparum and P. vivax.
- homologous DNA refers to equivalent linear sequences of DNA from organisms of the same genus, or of the same species, and which are identical, or substantially identical, differing one from the other merely by the substitution of equivalent alleles or by virtue of the degeneracy of the genetic code, and which encode identical or substantially identical proteins in two or more species within that genus, or two or more strains within that species, such proteins, referred to as homologous proteins or antigenic homologues, having substantially the same structures and properties and performing substantially the same or equivalent biological functions in each of the strains or species referred to, the terms homology, homologous, homologue etc, being construed accordingly.
- liver stage schizonts of P. berghei were cultured in human HepG2 cells using the techniques of Hollingdale and Suhrbier (see Hollingdale, 1983; and Suhrbier, et al., 1988, listed hereinafter).
- mice were immunized with HepG2 cells alone and were then treated with cyclophosphamide to suppress the subsequent response against the HepG2 cells.
- the animals were immunised three times with freeze- thawed 48-hour EE schizonts grown as above (approximately 2.5 x lO*-- cells with a 10-20% infection rate) given at 2 week intervals.
- Assay of the serum by indirect immunofluorescence on acetone-fixed cultured EE schizonts in HepG2 cells showed that although some HepG2 background reactivity occured, individual mice exhibited significant antibody reactivity to the parasite.
- mice were innoculated intravenously with 10 4 sporozoites on each of two succeeding days.
- day 6 and/or 7 after sporozoite inoculation when a Giemsa-stained blood smear showed positive blood parasitemia, the mouse was sacrificed and the spleen removed for fusion.
- the fusion protocol was performed as described by Winger, et al (1987).
- the supernatants of the resulting hybridomas were screened by indirect immunofluorescence on live and acetone fixed cultured liver schizonts, washed parasitized blood smears and smeared air-dried sporozoites.
- Monoclonal antibodies 17.9.15 (specific to an ookinete surface antigen Winger, et al., 1987), 17.6.1 (binding to an integral antigen of liver merozoites and all blood stage parasites; Suhrbier, et al., 1989b), 23.8.1 (an anti-cicumsporozoite protien antibody, data not shown) and anti-Pbl 1 (Plasmodium berghei liver 1 obtained as above) were purified from ascites fluid (Reik, et al 1987). All the antibodies were of the IgG 1 subclass. Protein levels were determined using a Biorad protein standard and by spectrophotometric analysis at 280nm.
- 13mm coverslips with a confluent monolayer of HepG2 cells were infected with approximately 2x10 ⁇ sporozoites in the presence of lmg/ml of purified anti-Pbl 1 or the same concentration of control antibody 17.6.1.
- the parasites were then cultured for 48 hours in the presence of antibodies before being fixed and parasite numbers, size and maturity determined by light microscopy.
- the fusion produced a total of 34 clones, of which 16 reacted with both liver and blood stages, 5 with sporozoites, 12 with HepG2 cells and 1, which reacted specifically with the liver stage.
- This monoclonal antibody designated anti-Pbll (Plasmodium berghei liver 1), showed no cross-reaction, using indirect i munofluorescent staining, with blood stage parasites, sporozoites or ookinetes of P. berghei.
- Liver stages of the closely related rodent .parasite P. yoelii cultured in primary mouse hepatocytes did not react with anti-Pbl 1.
- Liver stages of the human parasite P.vivax cultured in HepG2 cells also failed to react with anti-Pbl 1.
- Pbl 1 could first be clearly detected by indirect immunofluorescent antibody staining on intracellular P. berghei liver stage trophozoites 3 hours after invasion. As the trophozoites and schizont developed a peripheral staining pattern was observed, which was often associated with protrusions into the cytoplasm of the host cell. These protrusions frequently had the appearance of chains of small vesicles and whose presence correlated with the growth (presumably trophic) phase of parasite development. Parasites grown in W138 cells, a less satisfactory host cell, in which parasites are smaller and take longer to mature, showed an abundance of such structures.
- Pbl 1 was also expressed on intra-hepatic trophozoites derived from irradiated sporozoites.
- mice were infected with P. berghei ANKA strain, by blood passage. At 20-50% parasitaemia the mice were bled and the total of 25 mis of heparinized blood was filtered through a Whatman CF11 column to remove white blood cells. The blood was centrifuged at 1,500-3,000 g for 10 minutes and the cells resuspended in phosphate buffered saline (PBS) to a haematocrit of 50% and passed through the column to achieve a maximal final white blood cell/parasite ratio of 1:10,000. The filtrate was collected and spun again as described above to achieve a final packed preparation containing the parasites.
- PBS phosphate buffered saline
- DNA was extracted from the pelleted parasites as follows: To the pellet 30 ml of lysis buffer (50mm Tris-HCl pH 9, 100mm EDTA, 200 mm NaCl) was added; to this mixture proteinase K was added to a final concentration of lOO ⁇ g/ml, and the mixture incubated at 65°C for 30 mins. This was then followed by a second incubation at 37 °C for 1.5 hours. After this incubation, nucleic acids were extracted by the standard method of phenol/chloroform extraction (Maniatis et al.; 1982 Molecular Cloning, A Laboratory Manual, Cold Spring Harbour Laboratory, New York p. 458).
- RNAse enzyme a concentration of lOO ⁇ g/ml.
- phenol/chloroform extraction and ethanol precipitation were repeated to give a final DNA extract hereafter referred to as P. berghei DNA.
- a P. berghei genomic library was constructed from the P. berghei DNA as follows: lO ⁇ g of P. berghei DNA was digested with EcoRl using excess EcoRl enzyme (50U/ ⁇ g P. berghei DNA) in the presence of 20mM Tris-KCl pH 8.5, 2mM MgCl 2 and BSA (lO ⁇ g/ml) at 370°C for 22 hours (Polisky, B., et al, 1975, Proc. Nat. Acad. Sci. USA, 72, 3310-3314). The DNA was then used to construct a igtll genomic DNA library as described by Young, R.A. ⁇ c Davis, R.W. (1983, Proc. Nat. Acad. Sci. USA, 80, 1194- 1198). The conditions and reagents used to construct the library were as described by the manufacturers in the Amersham* cDNA yl gtll cloning kit (code No. RPN 1280).
- the library was screened with monoclonal antibody 23.46.7 using established protocols (Huynh, T.V., et al 1985 in DNA Cloning, a practical approach, edited by D.M. Glover, IRC Press, Oxford, Vol. 1, p. 49-108).
- the ⁇ gtll library was screened as plaques on a lawn of E. coli Y1090 cells.
- the library was plated out and incubated at 42 °C for 3 hours or until pin-prick plaques were seen.
- Nitrocellulous filter discs, with marked orientation, impregnated with 10m M IPTG were placed on the lawn and incubated for 2 hours at 37°C.
- the nitrocellulous filter was then removed and non-specific binding sites blocked with 5% milk powder in 0.1% Tween 20 in phosphate buffered saline.
- the filters were then incubated in 10 mis of monoclonal antibody 23.46.78 at 50 ⁇ g/ml in 0.1% Tween in PBS. This incubation was for 1.5 hours at room temperature.
- the positive clone descibed above, now identified as EcoPBl.l in gtll was amplified using standard PCR methods using the protocols and reagents provided in the Perkin-Elmer Cetus GeneAmp amplification reagent kit with AmpliTaqTM DNA polymerase (Cat. No. N. 801-0055, Perkin-Elmer Cetus).
- the reaction was set up under mineral oil according to their protocol, namely: 10 x reaction buffer; dNTP's mixture with 1.25mM of each dATP, dCTP, dGTP, dTTP; EcoPbl 1, Phage stock, freeze thawed; Forward primer; reverse primer, and Taq polymerase.
- Amplification involved the usual 3 steps of denaturation at 94°C for 1 min., annealing of primers at 50°C for 1 min., and extension using Taq polymerase at 72°C for 2 mins. This cycle was repeated for a total time of 5 hours.
- the primers forward and reverse were obtained from New England Biolabs, (Cat. No. 1218 and 1222).
- the PCR product obtained as above was frozen at -20°C and the mineral oil removed from the surface.
- the DNA was then phenol/chloroform extracted once and 50 ⁇ l of the aqueous phase was passed down a Sephadex CL6B column.
- the overhanging ends of the amplified DNA were filled using 2.5 U/ ⁇ l E. coli DNA polymerase Klenow fragment, obtained from Amersham International, (Cat. No. T21412), using standard methods, (Sambrook, Fritsch, Maniatus, Molecular Cloning, A lab manual, 2nd edition, Chapter 5, p 5.42). This reaction was at room temperature for 15 mins. and was stopped by heating at 65 °C for ID mins.
- the amplified DNA was then passed through a Sepharose CL6B column spun at 1,500 rpm for 3 mins.
- T4 polynucleotide kinase (Amersham International, Cat. No. 2020Y) was then added (10 U/ ⁇ l) and incubated in the presence of ligase buffer (200mM Tris HC1, pH 6, 50mM MgCl2, 50mM dithiothreitol, 500mg/ml BSA, lOmM ATP) at 37°C for 2 hours, the reaction being stopped by heat treatment at 65 °C for 10 mins.
- ligase buffer 200mM Tris HC1, pH 6, 50mM MgCl2, 50mM dithiothreitol, 500mg/ml BSA, lOmM ATP
- the following ligation was set up using M13mpl0 (Amersham N4531) and Puel3 (Pharmacia 27-4975-01). Both vectors were cut with Smal, and phosphatase treated. The PCR insert was then mixed with 10 x ligase buffer; vector (lOng/ ⁇ l); T4 DNA ligase (Amersham Cat No. T2050Y) the volume made up with H2O, and the mixture incubated overnight at 4°C.
- DH5 ⁇ (F * host cells for M13 and DH5 host cells for Pucl3 was then diluted 1/100 and 5 ⁇ l was used to transform DH5 ⁇ (F * host cells for M13 and DH5 host cells for Pucl3 using the protocol described by Hanahan, D. (1986, in DNA Cloning, a practical approach, edited by D.M. Glover, IRC Press, Oxford, Vol 1, p 109-135).
- DH5° nd DH5e F * cells from Gibco BRL Cat. Nos. 530 8265SA and 530 8264SA respectively.
- Transformed cells were plated out in the presence of lOO ⁇ m IPGT and 2% X-gal and incubated overnight at 37°C. Reeombinants were identified by their coloration. Blue plaques were parentals, M13 reeombinants were colourless and Pucl3 reeombinants were white.
- M13 reeombinants were picked and inoculated into 1.5ml 1/100 dilution of JM101 cells (Pharmacia, Cat. No. 27 1509 01) in 2 x TY medium (16 gms Bactotryptone, lOg yeast extract , 5g NaCl per litre) and grown at 37°C for 6 hours.
- 1 ml of clear supernatent from the plaque preparation was added to 250 ⁇ l of PEG NaCl (20% PEG 6,000; 2.5mM NaCl) and then mixed and incubated at room temperature for 15 mins.
- This preparation was then spun for 5 mins. in a microfuge, decanted and the white viral pellet (containing M13 phage) was then resuspended in lOO ⁇ l of TE buffer pH 8, (10m M Tris HCljlmM EDTA) and phenol/- chloroform was used to extract the DNA as described above.
- DNA was removed from the aqueous phase by sodium acetate precipitation at a final concentration of 0.3 M at pH 5.35 and subsequent addition of 2 1/2 vols. of absolute ethanol. DNA was later collected by centrifugation, washed in 70% ethanol, dried under vacuum and then resuspended in 25 ⁇ l TE buffer.
- Reeombinants were confirmed by running mini preps of the DNA on agarose gel against non-recombinant M13 single stranded DNA. Identification of reeombinants was based on the difference in size of the DNA from the two preparations. Positive clones obtained in M13 mini DNA preparations were sequenced using a Sequenase kit (USA Biochemical Corporation). The chain termination method (Sanger, F., Miklen, S. ⁇ 5c Coulson, A.R., 1977, Proc. Nat. Acad. Sci. USA 74, 5463-5467) was used. This technique (Tabor, S. & Richardson, CO., 1987, Proc. Nat. Acad. Sci. USA, 84, No.
- the insert Pbl 1 may be PCR amplified (see above) using synthetic oligonucleotides based on the above insert sequence.
- the PCR amplified insert can then be hexalabelled using 32 P (Feinberg and Vogelstein, 1984, Analytical Biochemistry, 137, 266-267) and then used to screen a P. falciparum gtll library and other available libraries (Sambrook, et al., 1989, (see above ref.) chapter 2, p 2.108-2.111 and p 2.114-2.117) constructed in the same way as the P. berghei library described above.
- the labelled insert may be used to screen southern blots of P. falciparum and P.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Plasmodium liver stage antigens are disclosed as well as cDNA sequences encoding such antigens of P.berghei and including homologous sequences of P.vivax and P.Falciparum.
Description
PLASMQDIUM LIVER STAGE ANTIGENS
This invention relates to the isolation and production of aπtigenic proteinaceous material from parasites of the genus Plasmodium, the production of monoclonal antibodies responsive thereto, and anti-malarial vaccines containing them.
The search for an effective anti-malarial vaccine has been hampered by two main factors: the low immunogenicity of the malarial parasite and its extremely varied and complex life cycle.
Following the bite of the infective mosquito the mammalian malarial sporozoite invades the hepatocyte wherein it multiplies for the next 2-15 days (dependant on the parasite species). Thereafter liver merozoites are released into the blood stream in which the intra-erthrocytic sexual and pathogenic asexual stages then proliferate initiating the blood stage of the disease responsible for the symptoms and pathology of malaria. Malaria vaccines based on antigens from the sporozoite (Herrington, et al., 1987), asexual blood stages (Patarroyo, et al., 1988) and sexual stages (Carter, et al., 1988) are currently being evaluated. In contrast liver stages antigens have been little studied as possible vaccine candidates because these intracellular stages were considered to be inaccessible to the immune system of the host (Cox, 1988). It is now clear from studies in rodent models (P. berghei and P. yoelii), however, that a substantial part of the protection afforded by immunising with irradiated sporozoites results from CD8+ T cell activity directed against the infected hepatocyte rather than from antibodies directed against the circumsporozoite proteins (CSP) on the circulating sporozoites (Weiss, 1987; Schofield, et al., 1987; Hoffman, et al., 1989). Processed CSP associated with the class 1 major histocompatability complex on the surface of the infected liver cell appears to be one target for such cytotoxic T cells (Kumar, et al., 1988; Sadoff, et al., 1988 ; Hoffman, et al., 1989a; Romero, et al., 1989). The single CD8+ T cell epitope of P. falciparum CSP shows a high degree of polymorphism (Loc yer, et al., 1989) and the response to it may also be geneticaDy restricted (Good, et al., 1988). It is still unclear to what extent these phenomena compromise the use of the CSP as the basis for a synthetic vaccine (De Groot, et al., 1989; Hoffman, et al., 1989b; De la Cruz, et al., 1988). The large number of blood stage antigens also expressed in the liver
stage (Danforth, Orjih <k Nussenzweig, 1978; Szarfman, et al., 1987, Suhrbier, et al., 1989a) and those antigens specific to the liver stage (Druihle, et al., 1984; Guerin-Marshand, et al., 1987) may all be potential targets for protective CD8+ T cells (Townsend ic Bodmer, 1989). Studies which have shown that the liver stage parasite can be killed by cytokines (principally gamma interferon) (Mazier, et al., 1988; Scholfield, et al., 1987) and phagocytes (Shortt & Garnham, 1984; Terzakis, et al., 1979; Meis, et al., 1987) further highlight the need to identify the antigens relevant to liver stage immunity.
In accordance with the present invention a liver stage antigen (Pbl 1) has been identified and isolated from cultures of Plasmodium berghei and a monoclonal antibody (anti-Pbl 1) produced specific to that antigen.
In its broadest aspects, therefore, the present invention contemplates:
1. A purified isolate comprising the P. berghei liver stage antigen Pbl 1, and Pbl 1 homologues from the genus Plasmodium, especially P. falciparum and P. vivax (referred to herein as homologous Pbl 1).
2. Liver stage antigens according to 1 obtained by the expression of genomic or cDNA encoding therefor in an expression vehicle.
3. Monoclonal antibodies specific to Plasmodium liver stage antigens according to 1 or 2.
4. Anti-malarial vaccines comprising a Plasmodium liver stage antigen according to 1 or 2, or a monoclonal antibody according to 3.
5. Genomic or cDNA fragments encoding Plasmodium liver stage antigens according to 1.
6. Transfection vectors containing a genomic or cDNA fragment according to 5 and capable of expressing Pbl 1 or homologous Pbl 1 in a host cell.
7. Transfected cells containing an expression vector containing a genomic or cDNA fragment according to 5 and capable, when cultured, of expressing Pbl 1 or homologous Pbl 1.
8. A hybridoma producing monoclonal antibody according to 3.
In a more specific aspect, the present invention provides:
1.1 A purified isolate comprising the liver stage antigen of P.berghei identified herein as Pbl 1.
3.1 The monoclonal antibody: anti-Pbl 1 (23.46.78).
5.1 A genomic or cDNA fragment encoding P.berghei liver stage antigen Pbl 1. According to preliminary analysis this sequence has the following properties.
It is 314 base pairs in length; it has no stop codons; it was in open reading frame with B-galactosidase; it has an Eco Rl site at one end; it is very AT rich (a characteristic of malarial DNA); it codes for 103 amino-acids with a combined M.W. of 12,082, i.e. it is only a fraction
(ca 1/3-1/4) of the native molecule; the sequence has no homology with any other sequence in the available gene database.
The sequence described thus far is set out in the appendix hereto as
SEQ. ID. No. 1.
6.1 An expression vector containing a genomic or cDNA fragment according to 5.1.
7.1 A host bacterium transfeeted with a vector according to 6.1 and capable when cultured of producing Pbl 1.
7.2 E. coli clone Eco.Pbl 1.
8.1 A bybridoma producing monoclonal antibody 23.46.7 (mono¬ clonal anti-Pbl 1.)
The P. berghei liver stage antigen identified herein as Pbl 1 has been identified in vivo as localised to the parasitophorous vacuole, i.e. the space surrounding the infecting parasite in the infected hepatocyte, and on the surface of the parasitophorous vacuole membrane . Molecular weight studies on the isolated antigen indicate a molecular weight (Mr) of 35 + 5 kDA. The antigen is specifically recognised by monoclonal antibody 23.46.7 (hereinafter described). The antigen is expressed throughout the liver stage of the infection by P. berghei from 3-5 hours post-invasion by the infecting sporozoites to the release of the merzoites from the liver into the blood stream.
As already indicated, the present invention also extends to Pbl 1 homologues from parasites of the genus Plasmodium, and more especially the human parasites P. falciparum and P. vivax.
As referred to herein, homologous DNA refers to equivalent linear sequences of DNA from organisms of the same genus, or of the same species, and which are identical, or substantially identical, differing one from the other merely by the substitution of equivalent alleles or by virtue of the degeneracy of the genetic code, and which encode identical or substantially identical proteins in two or more species within that genus, or two or more strains within that species, such proteins, referred to as homologous proteins or antigenic homologues, having substantially the same structures and properties and performing substantially the same or equivalent biological functions in each of the strains or species referred to, the terms homology, homologous, homologue etc, being construed accordingly.
Experimental
Production of anti-Pbl 1 monoclonal antibody
In the initial stage, 48-hour liver stage schizonts of P. berghei were cultured in human HepG2 cells using the techniques of Hollingdale and Suhrbier (see Hollingdale, 1983; and Suhrbier, et al., 1988, listed hereinafter).
In a separate stage BALB/c mice were immunized with HepG2 cells alone and were then treated with cyclophosphamide to suppress the subsequent response against the HepG2 cells. After the three week recovery period the animals were immunised three times with freeze- thawed 48-hour EE schizonts grown as above (approximately 2.5 x lO*-- cells with a 10-20% infection rate) given at 2 week intervals. Assay of the serum by indirect immunofluorescence on acetone-fixed cultured EE schizonts in HepG2 cells showed that although some HepG2 background reactivity occured, individual mice exhibited significant antibody reactivity to the parasite. After 5 months the mice were innoculated intravenously with 104 sporozoites on each of two succeeding days. On day 6 and/or 7 after sporozoite inoculation, when a Giemsa-stained blood smear showed positive blood parasitemia, the mouse was sacrificed and the spleen removed for fusion. The fusion protocol was performed as described by Winger, et al (1987). The supernatants of the resulting hybridomas were screened by indirect immunofluorescence on live and acetone fixed cultured liver schizonts, washed parasitized blood smears and smeared air-dried sporozoites. Ascites fluid of selected monoclonal antibodies, which had immunofluorescent titres of between 1/100,000 and 1/500,000 on liver parasites, were used at 1/50 dilutions on thick films of highly parasitized blood to verify the liver specificity of the monoclonal antibodies.
PASSIVE IMMUNISATION TRIALS
Monoclonal antibodies 17.9.15 (specific to an ookinete surface antigen Winger, et al., 1987), 17.6.1 (binding to an integral antigen of liver merozoites and all blood stage parasites; Suhrbier, et al., 1989b), 23.8.1 (an anti-cicumsporozoite protien antibody, data not shown) and anti-Pbl 1
(Plasmodium berghei liver 1 obtained as above) were purified from ascites fluid (Reik, et al 1987). All the antibodies were of the IgG 1 subclass. Protein levels were determined using a Biorad protein standard and by spectrophotometric analysis at 280nm. Using an ELISA for murine gamma interferon, no gamma interferon was detected in these preparations of levels of 97pcg or 1U per mg IgG. In one experiment the antibodies were further purified on a Protein G affinity column (Biorad). In the series of six experiments, lmg of purified monoclonal antibody of PBS was injected intravenously into groups of 3 or 4 mice 24 hours after infection with equal numbers of sporozoites (approx. 5x10s) and blood parasitemias were monitored on days 5, 6, 7 and 8 post infection. The experiments were performed in a double blind manner and Giesma stained smears were randomised and coded prior to reading (lO^rbc/slide).
13mm coverslips with a confluent monolayer of HepG2 cells were infected with approximately 2x10^ sporozoites in the presence of lmg/ml of purified anti-Pbl 1 or the same concentration of control antibody 17.6.1. The parasites were then cultured for 48 hours in the presence of antibodies before being fixed and parasite numbers, size and maturity determined by light microscopy.
Results
The fusion produced a total of 34 clones, of which 16 reacted with both liver and blood stages, 5 with sporozoites, 12 with HepG2 cells and 1, which reacted specifically with the liver stage. This monoclonal antibody, designated anti-Pbll (Plasmodium berghei liver 1), showed no cross-reaction, using indirect i munofluorescent staining, with blood stage parasites, sporozoites or ookinetes of P. berghei. Liver stages of the closely related rodent .parasite P. yoelii cultured in primary mouse hepatocytes did not react with anti-Pbl 1. Liver stages of the human parasite P.vivax cultured in HepG2 cells (Hollingdale, 1988) also failed to react with anti-Pbl 1.
Pbl 1 could first be clearly detected by indirect immunofluorescent antibody staining on intracellular P. berghei liver stage trophozoites 3 hours after invasion. As the trophozoites and schizont developed a peripheral staining pattern was observed, which was often associated with protrusions into the cytoplasm of the host cell. These protrusions frequently had the appearance of chains of small vesicles and whose presence correlated with
the growth (presumably trophic) phase of parasite development. Parasites grown in W138 cells, a less satisfactory host cell, in which parasites are smaller and take longer to mature, showed an abundance of such structures.
When maturing the parasite segments, first to form cytomeres and subsequently merzoites, antigens associated with the parasite plasmalemma and/or parasotiphorous vacuole are invaginated. During this period the peripheral staining pattern of anti-Pbl 1 was maintained indicating that Pbl 1 is associated with the parasitophorous vacuole and its limiting membrane (PVM), which does not invaginate during segmentation of the parasite. Preliminary immunoelectron microscopy studies have confirmed this localisation. The pattern seen in segmenters would be consistent with localisation on the PVM, which has by this stage been disrupted by the emerging merozoites. No staining was detected on the surface of the infected cells or on the free liver merozoites, which had broken away from the segmenters.
Pbl 1 was also expressed on intra-hepatic trophozoites derived from irradiated sporozoites.
When anti-Pbl 1 monoclonal antibodies were passively transferred to mice given a sporozoite inoculum 24 hours previously, the course of the sebsequent parasitemia appeared to be slightly delayed by approximately 12 hours when compared to control hosts inoculated with heterologous monoclonal antibodies or phosphate buffered saline (PBS).
Pbl 1 expression in E. coli.
1. Construction P. berghei DNA Library
20 mice were infected with P. berghei ANKA strain, by blood passage. At 20-50% parasitaemia the mice were bled and the total of 25 mis of heparinized blood was filtered through a Whatman CF11 column to remove white blood cells. The blood was centrifuged at 1,500-3,000 g for 10 minutes and the cells resuspended in phosphate buffered saline (PBS) to a haematocrit of 50% and passed through the column to achieve a maximal final white blood cell/parasite ratio of 1:10,000. The filtrate was collected and spun again as described above to achieve a final packed preparation containing the parasites.
DNA was extracted from the pelleted parasites as follows: To the pellet 30 ml of lysis buffer (50mm Tris-HCl pH 9, 100mm EDTA, 200 mm NaCl) was added; to this mixture proteinase K was added to a final concentration of lOOμg/ml, and the mixture incubated at 65°C for 30 mins. This was then followed by a second incubation at 37 °C for 1.5 hours. After this incubation, nucleic acids were extracted by the standard method of phenol/chloroform extraction (Maniatis et al.; 1982 Molecular Cloning, A Laboratory Manual, Cold Spring Harbour Laboratory, New York p. 458). The purified nucleic acids were ethanol precipitated and the RNA was digested from this precipitate by the addition of RNAse enzyme to a concentration of lOOμg/ml. Following this digestion, the phenol/chloroform extraction and ethanol precipitation were repeated to give a final DNA extract hereafter referred to as P. berghei DNA.
A P. berghei genomic library was constructed from the P. berghei DNA as follows: lOμg of P. berghei DNA was digested with EcoRl using excess EcoRl enzyme (50U/μg P. berghei DNA) in the presence of 20mM Tris-KCl pH 8.5, 2mM MgCl2 and BSA (lOμg/ml) at 370°C for 22 hours (Polisky, B., et al, 1975, Proc. Nat. Acad. Sci. USA, 72, 3310-3314). The DNA was then used to construct a igtll genomic DNA library as described by Young, R.A. όc Davis, R.W. (1983, Proc. Nat. Acad. Sci. USA, 80, 1194- 1198). The conditions and reagents used to construct the library were as described by the manufacturers in the Amersham* cDNA yl gtll cloning kit (code No. RPN 1280).
* Amersham International, Amersham, Bucks
2. Screening of the library with monoclonal antibody and selection of positive clone.
The library was screened with monoclonal antibody 23.46.7 using established protocols (Huynh, T.V., et al 1985 in DNA Cloning, a practical approach, edited by D.M. Glover, IRC Press, Oxford, Vol. 1, p. 49-108).
The λgtll library was screened as plaques on a lawn of E. coli Y1090 cells. The library was plated out and incubated at 42 °C for 3 hours or until pin-prick plaques were seen. Nitrocellulous filter discs, with marked orientation, impregnated with 10m M IPTG were placed on the lawn and incubated for 2 hours at 37°C. The nitrocellulous filter was then removed
and non-specific binding sites blocked with 5% milk powder in 0.1% Tween 20 in phosphate buffered saline. The filters were then incubated in 10 mis of monoclonal antibody 23.46.78 at 50μg/ml in 0.1% Tween in PBS. This incubation was for 1.5 hours at room temperature. The filters were then washed in 0.1% Tween 20/PBS for 20 mins.; this wash was repeated 3 times. Horseradish peroxidase -labeled goat-anti mouse IgG (Biorad) was used at a dilution of 1/1,000 in wash buffer to bind to the first antibody, by incubation at room temperature for 1.5 hours. The filters were then washed as above and incubated in diaminobenzidine substrate at a final concentration of 500μg/ml and 20μl of 30% hydrogen peroxide in 100 mis phosphate buffered saline. Positive plaques were then aligned with the original plates to identify and select positive colonies. These were then rescreened repeatedly using the above method until a pure stock of the clone was obtained.
3. Amplification by PCR transfer of DNA insert into N13 NP10
The positive clone descibed above, now identified as EcoPBl.l in gtll was amplified using standard PCR methods using the protocols and reagents provided in the Perkin-Elmer Cetus GeneAmp amplification reagent kit with AmpliTaq™ DNA polymerase (Cat. No. N. 801-0055, Perkin-Elmer Cetus). The reaction was set up under mineral oil according to their protocol, namely: 10 x reaction buffer; dNTP's mixture with 1.25mM of each dATP, dCTP, dGTP, dTTP; EcoPbl 1, Phage stock, freeze thawed; Forward primer; reverse primer, and Taq polymerase.
Amplification involved the usual 3 steps of denaturation at 94°C for 1 min., annealing of primers at 50°C for 1 min., and extension using Taq polymerase at 72°C for 2 mins. This cycle was repeated for a total time of 5 hours. The primers (forward and reverse) were obtained from New England Biolabs, (Cat. No. 1218 and 1222).
4. Insertion of EcoPbl 1 into M13mpl0 and Puc 13
The PCR product obtained as above was frozen at -20°C and the mineral oil removed from the surface. The DNA was then phenol/chloroform extracted once and 50μl of the aqueous phase was passed
down a Sephadex CL6B column. The overhanging ends of the amplified DNA were filled using 2.5 U/μl E. coli DNA polymerase Klenow fragment, obtained from Amersham International, (Cat. No. T21412), using standard methods, (Sambrook, Fritsch, Maniatus, Molecular Cloning, A lab manual, 2nd edition, Chapter 5, p 5.42). This reaction was at room temperature for 15 mins. and was stopped by heating at 65 °C for ID mins.
The amplified DNA was then passed through a Sepharose CL6B column spun at 1,500 rpm for 3 mins. T4 polynucleotide kinase (Amersham International, Cat. No. 2020Y) was then added (10 U/μl) and incubated in the presence of ligase buffer (200mM Tris HC1, pH 6, 50mM MgCl2, 50mM dithiothreitol, 500mg/ml BSA, lOmM ATP) at 37°C for 2 hours, the reaction being stopped by heat treatment at 65 °C for 10 mins. (Sambrook, Fritsch, Maniatis, Molecular Cloning, A lab manual, 2nd edition, chapter 5, p 5.68). The PCR amplified DNA was taken for ligation to the vectors M13mpl0 and Pucl3.
The following ligation was set up using M13mpl0 (Amersham N4531) and Puel3 (Pharmacia 27-4975-01). Both vectors were cut with Smal, and phosphatase treated. The PCR insert was then mixed with 10 x ligase buffer; vector (lOng/μl); T4 DNA ligase (Amersham Cat No. T2050Y) the volume made up with H2O, and the mixture incubated overnight at 4°C.
The ligation mix was then diluted 1/100 and 5μl was used to transform DH5σ(F* host cells for M13 and DH5 host cells for Pucl3 using the protocol described by Hanahan, D. (1986, in DNA Cloning, a practical approach, edited by D.M. Glover, IRC Press, Oxford, Vol 1, p 109-135). (DH5° nd DH5e(F* cells from Gibco BRL Cat. Nos. 530 8265SA and 530 8264SA respectively). Transformed cells were plated out in the presence of lOOμm IPGT and 2% X-gal and incubated overnight at 37°C. Reeombinants were identified by their coloration. Blue plaques were parentals, M13 reeombinants were colourless and Pucl3 reeombinants were white.
5. Ml 3 miniprep procedure for the preparation of single stranded DNA
M13 reeombinants were picked and inoculated into 1.5ml 1/100 dilution of JM101 cells (Pharmacia, Cat. No. 27 1509 01) in 2 x TY medium (16 gms Bactotryptone, lOg yeast extract , 5g NaCl per litre) and grown at 37°C for 6 hours.
1 ml of clear supernatent from the plaque preparation (spun cells 2 x in Eppendorf centrifuge) was added to 250μl of PEG NaCl (20% PEG 6,000; 2.5mM NaCl) and then mixed and incubated at room temperature for 15 mins.
This preparation was then spun for 5 mins. in a microfuge, decanted and the white viral pellet (containing M13 phage) was then resuspended in lOOμl of TE buffer pH 8, (10m M Tris HCljlmM EDTA) and phenol/- chloroform was used to extract the DNA as described above. DNA was removed from the aqueous phase by sodium acetate precipitation at a final concentration of 0.3 M at pH 5.35 and subsequent addition of 2 1/2 vols. of absolute ethanol. DNA was later collected by centrifugation, washed in 70% ethanol, dried under vacuum and then resuspended in 25μl TE buffer. Reeombinants were confirmed by running mini preps of the DNA on agarose gel against non-recombinant M13 single stranded DNA. Identification of reeombinants was based on the difference in size of the DNA from the two preparations. Positive clones obtained in M13 mini DNA preparations were sequenced using a Sequenase kit (USA Biochemical Corporation). The chain termination method (Sanger, F., Miklen, S. <5c Coulson, A.R., 1977, Proc. Nat. Acad. Sci. USA 74, 5463-5467) was used. This technique (Tabor, S. & Richardson, CO., 1987, Proc. Nat. Acad. Sci. USA, 84, No. 14, 4767-4771) required the synthesis of a DNA strand by a modified bacteriphage T7 DNA polymerase (Sequenase) using a single stranded DNA template from M13mpl0 and recombinant clones as described in the manufactures instructions ("Sequenase: Step-by-step protocols for DNA sequencing with Sequenase" 5th edition 1989, United States Biochemical Corporation).
Isolation of P. falciparum and P. vivax Homologues
The insert Pbl 1, already cloned into the M13 vector, may be PCR amplified (see above) using synthetic oligonucleotides based on the above insert sequence. The PCR amplified insert can then be hexalabelled using 32P (Feinberg and Vogelstein, 1984, Analytical Biochemistry, 137, 266-267) and then used to screen a P. falciparum gtll library and other available libraries (Sambrook, et al., 1989, (see above ref.) chapter 2, p 2.108-2.111 and p 2.114-2.117) constructed in the same way as the P. berghei library described above.
Alternatively the labelled insert may be used to screen southern blots of P. falciparum and P. vivax restriction digested DNA using standard protocols (Sambrook, et al., 1989 (See above ref.) chapter 9, p 9.31-9.40 and p 9.52-9.55) to identify any possible homology between these strains and P_. berghei. Following identification of the P. falciparum and P. vivax homologues by the procedures outlined above, these homologues may be isolated and subeloned utilising the procedures described above for P_^ berghei to obtain finally the desired homologous Pbl 1 antigens of j\ falciparum and P. vivax.
Deposit Details
E. coli clone Eco.Pbl 1
Deposited under the provisions of the Budapest Treaty on 30th August 1990 with the National Collection of Industrial and Marine Bacteria (NCIMB), Aberdeen, Scotland, Deposit No. NCIMB 40314
Hybridoma cell line (23.46.78)
Deposited under the provisions of the Budapest Treaty on 18th September 1990 with the European Collection of Animal Cell Cultures ECACC, Porton Down, Deposit No. 90091801
Finally, when considering the scope of the present invention, it is to be taken into account that it is well known that various fragments of an antigen or antibody will, depending on the size and the location of that fragment, retain sufficient antigenic/specific binding (antibody) capacity that, as a practical matter, that fragment can be considered as substantially equivalent to the antigen/antibody in question. The terms antigen/antibody are therefore to be construed as covering such functionally equivalent fragments. Likewise references to DNA sequences are to be taken to include fragments, allelic and degenerative variants thereof retaining for practical purposes the functionality of the complete sequence.
APPENDIX
SEO ID No . 1
Sequence type : Nucl eotide
Sequence length: 314 base pairs
Strandedness: Single
Topology: Linear
Molecule type: Genomic DNA
Original source organism: P.berghei
Immediate experimental source: E.coli clone Eco.Pbl 1 (NCIMBL 40714)
Features: from bp - 1 to -17 ) contiguous nucleotide sequences of and bp 315 to 323: ) the λgt 11 vector
bp 1 to 314 putative peptide encoding sequence.
SEO ID No. 1
5' cccgtca gtatcggcgg AATTTTTTTG TGTAGATGGA GATTCTAGCT 30
GTTCTTGTTT TTTTGTTTCT GACGATGATG 60
ATGTTGATGA TTCTTGTTGT CGTGCTAATT 90
CACCAGAAAA ATATATAGAA GAATCTCATA 120 AGCACTACAC AAAAGGGTTT CTAGAACAAT 150
ATACAGAGCC CAAACCAAGC GATCATACAT 180
ACAGTTATAC CCCCACTGAA GAAGCATATA 211
ACACACATTA TATGGCATCA GATACTCATG 240
AAGATTATGG CAAACTATTT ACAGATGAAC 270 ATAAGGACGA AATAAATGAT AATATAGTTT 300
ATCACGATGA ATTC cagctgagc 3' 314
Claims
1. Purified isolates comprising the P.berghei liver stage antigen Pbl 1 and homologues thereof from other parasites of the genus Plasmodium.
2. Homologous Pbl 1 from parasites of the species P.falciparum and P.vivax.
3. Liver stage antigens according to claim 1 or 2 obtained by the expression of a genomic or cDNA fragment encoding therefor in an expression vehicle.
4. Liver stage antigens according to claim 3 wherein said genomic or cDNA fragment comprises the sequence SEQ ID No. 1 or a substantially (at least 90%) homologous sequence.
5. A purified isolate of P.berghei liver stage antigen Pbl 1.
6. Cloned P.berghei liver stage antigen Pbl 1.
7. Monoclonal antibodies specific to Plasmodium liver stage antigens as claimed in any one of claims 1 to 6.
8. Monoclonal antibody 23.46.78.
9. An anti-malarial vaccine comprising a liver stage antigen according to any one of claims 1 to 6 or a monoclonal antibodv according to claim 7 or 8.
10. A genomic or cDNA fragment encoding a Plasmodium liver stage antigen as claimed in any one of claims 1 to 6.
11. A genomic or cDNA fragment encoding P.berghei liver stage antigen Pbl 1.
12. A genomic or cDNA fragment according to claim 11 wherein said fragment comprises the sequence SEQ ID No. 1 or a substantially (at least 90%) homologous sequence.
13. A transfection vector containing a genomic or cDNA fragment according to claim 10, 11 or 12.
14. A vector according to claim 13 comprising said genomic or cDNA fragment inserted into λgtll phage, M13 and Puc.
15. Transfected cells containing an expression vector according to claims 13 or 14 and capable when cultured of expressing the Pbl or homologous Pbl 1.
16. Transfected cells according to claim 15 which are bacterial cells.
17. E.coli. Pbl 1( CIMB 40314)
18. A hybridoma cell line capable of producing monoclonal antibody according to claims 7 or 8.
19. Hybridoma cell line 23.46.78 (ECACC Deposit No. 90091801).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909020438A GB9020438D0 (en) | 1990-09-19 | 1990-09-19 | Plasmodium liver stage antigens |
GB9020438.9 | 1990-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992005193A1 true WO1992005193A1 (en) | 1992-04-02 |
Family
ID=10682429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1991/001605 WO1992005193A1 (en) | 1990-09-19 | 1991-09-19 | Plasmodium liver stage antigens |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0549662A1 (en) |
JP (1) | JPH06500996A (en) |
AU (1) | AU8611491A (en) |
GB (1) | GB9020438D0 (en) |
WO (1) | WO1992005193A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992013884A1 (en) * | 1991-02-05 | 1992-08-20 | Institut Pasteur | Liver-stage-specific peptide sequences of p. falciparum bearing epitopes capable of stimulating the t lymphocytes |
US6270771B1 (en) | 1988-10-06 | 2001-08-07 | Institut Pasteur | Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes |
WO2007041216A2 (en) * | 2005-09-30 | 2007-04-12 | Seattle Biomedical Research Institute | Plasmodium liver stage antigens |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988005785A1 (en) * | 1987-02-09 | 1988-08-11 | Institut Pasteur | Molecules comprising at least one peptidic sequence carrying one or a plurality of epitopes characterizing a protein produced by p. falciparum in hepatocytes and compositions containing them |
-
1990
- 1990-09-19 GB GB909020438A patent/GB9020438D0/en active Pending
-
1991
- 1991-09-19 AU AU86114/91A patent/AU8611491A/en not_active Abandoned
- 1991-09-19 WO PCT/GB1991/001605 patent/WO1992005193A1/en not_active Application Discontinuation
- 1991-09-19 EP EP91916716A patent/EP0549662A1/en not_active Withdrawn
- 1991-09-19 JP JP3515789A patent/JPH06500996A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988005785A1 (en) * | 1987-02-09 | 1988-08-11 | Institut Pasteur | Molecules comprising at least one peptidic sequence carrying one or a plurality of epitopes characterizing a protein produced by p. falciparum in hepatocytes and compositions containing them |
Non-Patent Citations (6)
Title |
---|
BULLETIN OF THE WORLD HEALTH ORGANIZATION, Vol. 68, No. SUP, 1990, Geneva, Switzerland, pages 172-177, L. WINGER et al., "A Liver-Stage Specific Antigen of P. Berghei Identified by a Monoclonal Antibody". * |
BULLETIN OF THE WORLD HEALTH ORGANIZATION, Vol. 68, No. SUPP, 1990, Geneva, Switzerland, pages 158-164, C. MARCHAND et al., "How to Select Plasmodium Falciparum Pre-Erythrocytic Antigens in an Expression Library Without Defined Probe". * |
IMMUNOLOGY LETTERS, Vol. 25, No. 1-3, August 1990, Amsterdam, The Netherlands, pages 71-76, M. HOLLINGDALE et al., "Non-CS Pre-Erythrocytic Protective Antigens". * |
PARASITE IMMUNOLOGY, Vol. 12, No. 5, September 1990, OXFORD, GB, pages 473-481, A. SUHRBIER et al., "An Antigen Specific to the Liver Stage of Rodent Malaria Recognized by a Monoclonal Antibody". * |
PARASITOLOGY, Vol. 103, No. 1, August 1991, Cambridge, GB, pages 17-21, R. SINDEN et al., "The Development of Exo-Erythrocytic Schizonts of Plasmodium Berghei in Vitro from Gamma-Irradiated and Non-Irradiated Sporozoites: A Study Using Confocal Laser Scanning Microscopy". * |
THE JOURNAL OF IMMUNOLOGY, Vol. 145, No. 5, 1 September 1990, BALTIMORE, US, pages 1557-1563, J. LONDONO et al., "Secondary Structure and Immunogenicity of Hybrid Synthetic Peptides Derived from two Plasmodium Falciparum Pre-Erythrocytic Antigens". * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087231B2 (en) | 1987-02-09 | 2006-08-08 | Institut Pasteur | Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes |
US6270771B1 (en) | 1988-10-06 | 2001-08-07 | Institut Pasteur | Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes |
WO1992013884A1 (en) * | 1991-02-05 | 1992-08-20 | Institut Pasteur | Liver-stage-specific peptide sequences of p. falciparum bearing epitopes capable of stimulating the t lymphocytes |
US6319502B1 (en) | 1991-02-05 | 2001-11-20 | Institut Pasteur | Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes |
US7332595B2 (en) | 1991-02-05 | 2008-02-19 | Institut Pasteur | DNA sequences encoding peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes |
US7438917B2 (en) | 1991-02-05 | 2008-10-21 | Institut Pasteur | Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes |
WO2007041216A2 (en) * | 2005-09-30 | 2007-04-12 | Seattle Biomedical Research Institute | Plasmodium liver stage antigens |
WO2007041216A3 (en) * | 2005-09-30 | 2007-08-02 | Seattle Biomedical Res Inst | Plasmodium liver stage antigens |
US7722889B2 (en) | 2005-09-30 | 2010-05-25 | Seattle Biomedical Research Institute | Plasmodium liver stage antigens |
US8318183B2 (en) | 2005-09-30 | 2012-11-27 | Seattle Biomedical Research Institute | Plasmodium liver stage antigens |
Also Published As
Publication number | Publication date |
---|---|
AU8611491A (en) | 1992-04-15 |
EP0549662A1 (en) | 1993-07-07 |
GB9020438D0 (en) | 1990-10-31 |
JPH06500996A (en) | 1994-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gaur et al. | Parasite ligand–host receptor interactions during invasion of erythrocytes by Plasmodium merozoites | |
Culvenor et al. | Plasmodium falciparum: identification and localization of a knob protein antigen expressed by a cDNA clone | |
Coppel et al. | Variable antigen associated with the surface of erythrocytes infected with mature stages of Plasmodium falciparum | |
Onuma et al. | Theileria parasite infection in East Asia and control of the disease | |
Kun et al. | A putative Plasmodium falciparum exported serine/threonine protein kinase | |
NO843872L (en) | EXPRESSION OF PLASMODIUM FALCIPARUM POLYPEPTIDES FROM THE CLONET CDNA | |
US5925347A (en) | Viral vector vaccines comprising nucleic acids encoding eimeria proteins for poultry vaccination against coccidiosis | |
Sugiyama et al. | Production of recombinant SERA proteins of Plasmodium falciparum in Escherichia coli by using synthetic genes | |
US10213501B2 (en) | Three-component-multistage malaria vaccine | |
HU212506B (en) | Method for the preparation of recombinant vaccine against coccidiosis | |
CA2505724A1 (en) | Malaria vaccine | |
EP0153188B1 (en) | Improvements in or relating to the production of malaria vaccines | |
US20070098738A1 (en) | MSP-3-like family of genes | |
WO1992005193A1 (en) | Plasmodium liver stage antigens | |
Mahajan et al. | Genetic polymorphism in Plasmodium falciparum vaccine candidate antigens | |
EP1357128A1 (en) | The preparation and usage of plasmodium fusion antigen | |
Couffin et al. | Characterisation of PfSec61, a Plasmodium falciparum homologue of a component of the translocation machinery at the endoplasmic reticulum membrane of eukaryotic cells | |
Barale et al. | Plasmodium falciparum asparagine and aspartate rich protein 2 is an evolutionary conserved protein whose repeats identify a new family of parasite antigens | |
Kant et al. | Allelic forms of the knob associated histidine‐rich protein gene of Plasmodium falciparum | |
JPH06500990A (en) | new protein | |
EP0215059A1 (en) | cDNA CODING FOR PLASMODIUM FALCIPARUM GLYCOPHORIN BINDING PROTEINS WEIGHING 130,000 DALTONS AND 155,000 DALTONS | |
NZ231918A (en) | Eimeria tenella nucleic acid sequences, polypeptides and vaccines therefrom | |
WO1994012640A1 (en) | RECOMBINANT NUCLEIC ACID, POLYPEPTIDE MATERIAL CODED THEREBY AND TRANSMISSION BLOCKING VACCINE BASED THEREON FOR CONTROLLING THE MALARIA PARASITE $i(PLASMODIUM FALCIPARUM ) | |
JPH05508996A (en) | Cloning and expression of rhoptry-related proteins in Plasmodium falciparum | |
Scaife et al. | Antigens of Plasmodiwn falciparum blood stages with clinical interest cloned and expressed in E. coli |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991916716 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991916716 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1991916716 Country of ref document: EP |